scorecardresearchCipla Share Price 939.20
Mintgenie
Mintgenie

Cipla

BSE: 500087 | NSE: CIPLA | ISIN: INE059A01026 | SECTOR: Biotechnology & Drugs

₹939.20 0.00 (0%)

05 Jul 2022, 09:59 (IST)

  • Open

    940.00

  • High

    948.95

  • Low

    931.25

  • Prev Close

    930.35

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    -

  • Volume

    14.27K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics
  • 931.25
  • Intraday
  • 948.95
  • 850.00
  • 52 Wk H/L
  • 1,083.15
  • 837.35
  • DPR
  • 1,023.35

Key Metrics

- Mkt. Cap.

V

Volatility %

Market Sentiment

  • Neutral
B

Beta -

Genie Says

Influencer Count

87

Financials

  • Annual
  • Quarterly
  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available
View all

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)		52 Week
High		52 Week
Low		Market Cap.
(Cr)
View all

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    View all

    Simple Moving Averages

    DaysBSENSE

    Cipla is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    News

    View all

    Company Description

    • Large Cap
    • Automobiles

    • BSE

      500087

    • NSE

      CIPLA

    • ISIN

      INE059A01026

    Cipla Limited is an India-based company that is primarily engaged in the business of pharmaceuticals. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 46 manufacturing sites.

    Company Officers

    • Umang Vohra

      Global Chief Executive Officer, Managing Director, Executive Director

    • Samina Hamied

      Executive Vice Chairman of the Board

    • Dinesh Jain

      Interim Chief Financial Officer

    • Paul Miller

      CEO Cipla South Africa and Regional Head Africa and Access

    • Geena Malhotra

      Global Chief Technology Officer

    • Pradeep Bhadauria

      Global Chief Scientific Officer

    • Rajendra Chopra

      Compliance Officer, Company Secretary

    • Swapn Malpani

      Global Head Supply Chain

    • Raju Mistry

      Global Chief People Officer

    • Ranjana Pathak

      Global Head of Quality - Medical Affairs and Pharmacovigilance